What are the limit values for ginkgolic acid?

Ginkgolic acids are strictly limited to extremely low levels at the ppm scale across countries worldwide, as they carry clear multi-dimensional health hazards and are far from ordinary production by-product impurities.

These components are naturally abundant in the cuticle and episperm of ginkgo leaves. Conventional water extraction and alcohol extraction processes will dissolve them together with the target active ingredients like flavonoids and lactones, which can only be removed through dedicated procedures such as macroporous adsorption resin treatment and multi-stage extraction. The 5ppm or even lower limits set by various national pharmacopoeias are essentially designed with sufficient safety redundancy. They not only match the stable deacidification capacity of the industry, but also reduce the long-term low-dose exposure health risks to nearly zero. Meanwhile, this is the core hard threshold for the B-end industry to judge the quality control capability of suppliers – whether ginkgolic acids can be stably controlled below the compliance line directly distinguishes ordinary crude extracts from qualified refined products.

The hazards of ginkgolic acids go far beyond mild irritation: they are strong sensitizers. Even low-dose exposure can induce contact dermatitis, mucosal redness, itching and lip numbness in people with allergic constitutions. They also have definite cytotoxicity. At high concentrations, they can directly induce hepatocyte apoptosis, and long-term low-dose intake will cause occult liver enzyme elevation and chronic liver injury. They will also disrupt the body’s immune balance and induce chronic inflammation. When ingested in large amounts, they will irritate the gastrointestinal tract, accompanied by dizziness and irritability, and even convulsions in severe cases. Moreover, there is no specific antidote for such acute poisoning. Clinically, doctors can only use symptomatic treatments such as gastric lavage and fluid infusion to accelerate metabolism, leading to high risk of severe cases.

B-end Professional Standards for Ginkgolic Acid Limits in Global Markets

Ginkgolic acids are sensitizing and cytotoxic impurities that must be strictly controlled in Ginkgo Biloba Extract. The limit requirements vary across countries and markets, which directly determines the compliance access threshold for B-end products.

Standards in the Chinese Market

• Pharmaceutical grade (Chinese Pharmacopoeia 2020 Edition): The total ginkgolic acid content ≤ ‌5ppm‌, which is the mandatory access red line for pharmaceutical-grade Ginkgo Biloba Extract in China.
• Food/health product grade: The mainstream industry compliance requirement sets the total ginkgolic acid content ≤ ‌10ppm‌, and some leading factories can achieve the internal control standard of ≤5ppm at the pharmaceutical grade.
• Historical standard evolution: The 2015 edition of Chinese Pharmacopoeia once required the total ginkgolic acid content ≤10ppm, and the 2020 edition tightened it to 5ppm, aligning with the standards of mainstream international pharmacopoeias.

Standards in the EU Market

• EMA / European Pharmacopoeia (EP): The total ginkgolic acid content ≤ ‌5ppm‌, and the content of single ginkgolic acid components such as C13:0, C15:1 and C17:1 ≤ ‌1ppm‌, forming the world’s strictest component control system.
• German Commission E Monograph: It follows the total limit of 5ppm, which is the earliest official standard that brings ginkgolic acids into mandatory control, and directly affects the production specifications of world-famous medicinal Ginkgo Biloba Extracts such as EGb761.
• Food supplement track: EU food-grade products default to the same 5ppm limit as pharmaceutical-grade products, with no separate relaxation space.

Standards in the US Market

• United States Pharmacopeia (USP): The mandatory limit for total ginkgolic acid content ≤ ‌5ppm‌, which is the access bottom line for the dietary supplement track.
• High-end internal control standards in the industry: Leading brand supply chains generally set the internal control of total ginkgolic acid content ≤ ‌2ppm‌, and some top refined products can reach ≤1ppm to avoid FDA sampling inspection risks.
• Regulatory features: Although the FDA has not issued a separate monograph, it forces suppliers to provide ginkgolic acid test reports through the CGMP system for dietary supplements, and products exceeding the limit will be directly judged as adulterated.

Standards in Other Key Markets

• Japan’s Ministry of Health, Labour and Welfare: It refers to the USP standard and implements the total ginkgolic acid limit of ≤5ppm, and additionally requires the content of single component ≤2ppm for medicinal Kampo preparations.
• Emerging markets such as South Africa’s SAHPRA: There is no independent monograph, and they directly align with the mainstream international total ginkgolic acid limit of 5ppm, taking the third-party test report provided by suppliers as the access basis.

Additional Key Supplements for B-end Procurement

Grading system: In the industry, ginkgolic acid products are divided into four mainstream grades from low to high purity: 10ppm, 5ppm, 2ppm and 1ppm. The higher the grade, the higher the cost of the deacidification process.

Gold standard for detection: B-end compliance verification must adopt the HPLC-MS/MS triple quadrupole liquid chromatography-tandem mass spectrometry method. Ordinary HPLC-UV method cannot accurately detect trace ginkgolic acids at the 1ppm level.

Red line risk: Long-term intake of products with excessive ginkgolic acids will cause toxic and side effects such as telangiectasia, lip numbness and elevated liver enzymes. In 2026, China has included non-compliant ginkgo leaf preparations in the key monitoring blacklist.

We have dealt with numerous clients in the ginkgo leaf dietary supplement sector, many of whom have previously encountered situations where random inspections revealed ginkgolic acid levels in the raw material to be above the permitted limits, resulting in entire batches being detained. Consequently, when selecting suppliers, many now prioritise the quality control protocols of Nutralighting ginkgo leaf extract: it controls the leaf parts where ginkgolic acids are enriched from the planting stage, and adds two exclusive deacidification procedures after extraction. The measured ginkgolic acid content in some batches is stably controlled within 2ppm, far below the 5ppm red line of various national pharmacopoeias. The ratio of flavonoids and lactones is also fully aligned with the 24/6 standard (for 24/6 details, you can read What does the 24/6 specification of Ginkgo biloba leaf extract mean). It can directly meet the compliance requirements of multiple scenarios such as pharmaceutical grade and food grade. Many export-oriented clients use it as the core raw material, and their subsequent special sampling inspections by drug regulatory authorities in various countries are all smooth. They do not need to spend a lot of extra energy on repeated impurity verification, and the overall compliance stability of the supply chain is much more reassuring.